Therefore, similarly to IL-15, an altered SMAD-3 activity associated with specific genetic variants could modify the TGF-β-related transcriptional response impacting on both the tumor development and the antitumor FOLFIRI efficacy, finally affecting the patients’ prognosis. The gene discussed is SMAD3; the disease is neoplasm.